Your Prevention
Your Prevention
Tomorrow’s health is today’s prevention. Early screening for possible infectious diseases, e.g. sexually transmitted infections (STI), enables successful therapy, as well as the interruption of infection chains. Many infections can go undetected without signs. For this reason, it is important to get tested, safely and easily, yet with the highest sensitivity, from home without a long wait. We do not leave anyone alone with a positive test, but refer directly to experts, for an optimal treatment offer in the early stages of infection. We are currently expanding our portfolio with new discreet testing offers at costs that enable prevention for all.
Medical Labs
In almost all large laboratories, the technical infrastructure required for LAMPseq is already in place. At the heart of LAMPseq laboratory diagnostics are sequencing instruments from Illumina. Even small models – such as MiniSeq or MiSeq – offer an analysis throughput equivalent to the capacity of several hundred PCR instruments.
Our LAMPseq technology platform offers the possibility to analyze samples, e.g. blood reserves, for pathogens in an ultra-high- throughput process. You save time, personnel costs and laboratory space. We offer you a growing portfolio of tests in new application areas.
Of course, we are more than happy to advise you with fast and uncomplicated support for the implementation of LAMPseq technology in your laboratory.
Infection monitoring
Our technology platform has shown during the COVID-19 pandemic that LAMPseq offers the perfect testing procedure: many people can be tested in a short time with highest accuracy. Thus, it is already clear after a few hours who is infected. Our technology platform is also ready for the next pandemic or outbreak e.g. avian flu, swine fever, influenza, RSV. Many tests in a short time with high accuracy at a fraction of the cost. We can validate new targets for outbreak management, surveillance and sentinel studies on short notice.
Health data
High test numbers generate large amounts of data and these form the valuable basis for the further development of medicine, through new AI applications as well as epidemiological questions. Of course, the data is processed anonymously and DSGVO compliant. We work with leading experts in this field, please contact us.
LAMPseq Portfolio
- SARS-Q Kit
COVID-19
Screening and diagnosis of COVID-19/SARS-CoV-2 in ultra-high throughput.
In May 2022, LAMPseq Diagnostics has declared CE-conformity for its SARS-Q Kit. Our CE marked screening test is available. Get in touch.
✓ CE-marked (IVDD)
✓ Diagnostic Specificity – 100%
✓ Diagnostic Sensitivity – 98.45% (Ct40), 100% (Ct33)
✓ 100% equivalency for oro- and nasopharyngeal sampling
✓ Analytical Sensitivity – Limit of Detection (LoD) – 32.17 IU/mL1)
✓ Cross Reactivity – Not observed
✓ Interference – Not observed for a wide range of conditions
1)WHO International standard NIBSC 20/146
- STI
Sexually transmitted infections (STI) panel
In development: a multigene panel for STI outbreak management.
- FOUR COLD
SARS-CoV-2 + Flu A + Flu B + RSV
In development: a new tool for physicians treating patients with acute respiratory symptoms.
